Diverticulitis disease is a digestive condition that causes formation of sacs or small bulges in the wall of the large intestine. Although these sacs are most common in the sigmoid colon, they can occur in any part of the colon. Diverticulitis disease is caused by a variety of conditions, including a low-fiber diet, lack of physical activity, and some medications such as anti-inflammatory drugs, vitamin D deficiency, obesity, and smoking. Although the symptoms are mild and can be treated by exercise, lifestyle modifications, and antibiotics, if it get serious the inflamed pouches cause fever, severe abdominal pain, nausea, blood in stools, and requires surgery. Treatment for symptomatic diverticulitis disease is mostly based on symptoms. Conventional treatment of diverticulitis disease includes antibiotics, fiber, bowel rest, pain control, and medical surgery for selected cases. The research discusses recent advances in the medical treatment of diverticulitis diseases, such as the utilization of rifaximin, mesalamine, and probiotics, as the understanding of the disease evolves.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment
drugs for COVID-19. This, in turn, is expected to have a significant impact on the diverticulitis disease market.
Top Impacting Factors
Increase in prevalence obesity is expected to drive the growth of the market. In addition, surge in geriatric population leading to rise in patient population and rise in cigarette smoking population boost the growth of the diverticulitis disease market.
Moreover, increase in adoption of sedentary lifestyle, lack of exercise, a diet high in animal fat & low in fiber, and excessive use of certain medication such as steroids, opioids and NSAIDs are expected to boost the growth of the diverticular market. Continuous clinical trials going on rare disorders and increase in demand of drugs for the treatment of digestive disorders are projected to drive the growth of the diverticulitis disease market.
Furthermore, rise in incidence of gastrointestinal and digestive disorders augment the market growth. Rise in awareness about health and government initiatives to improve healthcare infrastructure further propel the diverticulitis disease market growth.
However, lack of patient awareness in developing countries and stringent Food & Drug Administration guidelines for the approval of new treatment or drugs restrain the growth of the diverticulitis market.
Market Trends
New Product Launches to Flourish the Market
In January 2020, Emmaus Life Sciences Inc. announced the preliminary results observed in the first patient in the company’s phase 1 study of diverticulitis treatment. The results were satisfactory and the company intends to continue the research and development process for novel drugs to treat diverticulitis
In May 2020, Hikma Pharmaceuticals PLC. launched Dicyclomine Hydrochloride Oral Solution for the treatment of various inflammatory bowel diseases, including diverticulitis.
Key Benefits of the Report
- This study presents the analytical depiction of the Diverticulitis disease market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Diverticulitis Disease Market Report
- Which are the leading players active in the Diverticulitis disease market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is Diverticulitis disease market?
- What is Diverticulitis disease market prediction in the future?
- Who are the leading global players in the Diverticulitis disease market?
- What are the current trends and predicted trends?
- What are the key benefits of the Diverticulitis disease market report?
Diverticulitis Disease Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Treatment |
|
 By Diagnosis |
|
 By End User |
|
 By Region |
|
 Key Market Players | Abbott Laboratories, Ardelyx Inc., Novartis AG, Astellas Pharma Inc., Synergy Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Sucampo Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Baxter, Pfizer Inc., Teva Pharmaceutical Industries Ltd. |
Loading Table Of Content...
